Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

6.06
-0.1400-2.26%
Post-market: 6.250.1900+3.14%19:08 EDT
Volume:1.05M
Turnover:6.45M
Market Cap:524.64M
PE:-2.90
High:6.26
Open:6.19
Low:6.01
Close:6.20
Loading ...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
02 May

Kura Oncology price target lowered to $11 from $32 at Barclays

TIPRANKS
·
02 May

Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs

GuruFocus.com
·
02 May

Kura Oncology Advances with Key NDA Submission

TIPRANKS
·
02 May

Kura Oncology Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
02 May

Kura Oncology: Promising Clinical Trial Results and Strong Financial Position Support Buy Rating

TIPRANKS
·
02 May

Kura Oncology’s Promising Future: Strong Financial Health and Successful Clinical Trials Drive Buy Rating

TIPRANKS
·
02 May

Kura Oncology reports Q1 EPS (66c), consensus (60c)

TIPRANKS
·
02 May

Kura Oncology: Q1 Earnings Snapshot

Associated Press Finance
·
02 May

Kura Oncology Q1 EPS $(0.66), Inline, Sales $14.11M Beat $7.73M Estimate

Benzinga
·
02 May

BRIEF-Kura Oncology Q1 Operating Expenses USD 78.808 Million

Reuters
·
02 May

Kura Oncology Inc Q1 Shr View $-0.39 -- Lseg Ibes Data

THOMSON REUTERS
·
02 May

Kura Oncology Inc: Qtrly Loss per Share $0.66

THOMSON REUTERS
·
02 May

Kura Reports Dosing in Phase 1 Ziftomenib Combination Trial

MT Newswires Live
·
28 Apr

Kura Oncology’s Strategic Advancements and Market Potential Justify Buy Rating

TIPRANKS
·
28 Apr

Kura Oncology’s Strategic Advances and Promising Trials Garner Buy Rating from Analyst

TIPRANKS
·
28 Apr

BRIEF-Kura Oncology Announces First Patients Dosed In Phase 1 Combination Trial Of Ziftomenib For The Treatment Of Advanced Gist

Reuters
·
28 Apr

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

GlobeNewswire
·
28 Apr

Kura Oncology to Report First Quarter 2025 Financial Results

GlobeNewswire
·
24 Apr

Kura Oncology’s Strategic Milestones and Financial Strength Bolster Buy Rating

TIPRANKS
·
09 Apr